This study presents, for the first time, the therapeutic effects of PARPi in ccRCC with mutations in genes associated with the mutation of RAD51C and CDK12. Particularly noteworthy are cases harboring mutations in RAD51C and CDK12 genes, where the effectiveness of PARPi treatment has already gained FDA approval in prostate cancer. This evidence concerns the gene RAD51C and prostate carcinoma.